Emerging treatment options for prostate cancer

被引:7
|
作者
Atiq, Mohammad [1 ]
Chandran, Elias [1 ]
Karzai, Fatima [1 ]
Madan, Ravi A. [1 ]
Aragon-Ching, Jeanny B. [2 ,3 ]
机构
[1] NCI, Genitourinary Malignancy Branch, Bethesda, MD USA
[2] Inova Schar Canc Inst, GU Med Oncol, Fairfax, VA 22031 USA
[3] Univ Virginia, Med Educ, Charlottesville, VA USA
关键词
Anti-androgen; immunotherapy; metastatic prostate cancer; radioligands; prostate cancer; DOUBLE-BLIND; PHASE-I; INCREASED SURVIVAL; SIPULEUCEL-T; OPEN-LABEL; CASTRATION; ENZALUTAMIDE; ABIRATERONE; THERAPY; PLACEBO;
D O I
10.1080/14737140.2023.2208352
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionProstate cancer treatment has rapidly evolved in the past few years. Androgen deprivation therapy has been the backbone of treatment for locally advanced and metastatic prostate cancer, but incremental benefits in survival have been shown by adding androgen-receptor pathway inhibitors (ARPI) across various spectrums of disease state. In addition, docetaxel chemotherapy remains the first-line chemotherapy regimen available with survival benefits shown with triplet therapy in those who are chemotherapy eligible. However, disease progression remains inevitable and novel agents such as radioligand therapy with lutetium have shown improvement in survival.Areas coveredThis review discusses the pivotal trials that led to the U.S. FDA approval of agents utilized in metastatic prostate cancer and explores the use of novel agents including prostate-specific membrane antigen-targeting agents, radioligands, cell-based therapy, chimeric antigen receptor T-cell, BiTE, and antibody drug conjugates.Expert opinionTreatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has evolved beyond additional agents with ARPI and/or docetaxel, including other treatments with sipuleucel-T, radium, cabazitaxel, PARP inhibitors, and lutetium, which have specific indications and roles in sequencing. Novel therapies remain critically needed after progression from lutetium.
引用
收藏
页码:625 / 631
页数:7
相关论文
共 50 条
  • [41] Gynecomastia in patients with prostate cancer: update on treatment options
    R Autorino
    S Perdonà
    M D'Armiento
    M De Sio
    R Damiano
    L Cosentino
    G Di Lorenzo
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 109 - 114
  • [42] Low and intermediate risk prostate cancer: Treatment options
    Minana-Lopez, Bernardino
    Reina-Alcaina, Leandro
    Rivero-Guerra, Angela
    Rosino-Sanchez, Antonio
    Izquierdo-Morejon, Emilio
    Pietricica, Bogdan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (06): : 260 - 270
  • [43] A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer
    Moussa, Mohamad
    Papatsoris, Athanasios
    Sryropoulou, Despoina
    Chakra, Mohamed Abou
    Dellis, Athanasios
    Tzelves, Lazaros
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (13) : 1685 - 1728
  • [44] Novel focal therapy treatment options for prostate cancer
    Werntz, Ryan P.
    Eggener, Scott E.
    CURRENT OPINION IN UROLOGY, 2018, 28 (02) : 178 - 183
  • [45] Treatment options in androgen-independent prostate cancer
    Lara, PN
    Meyers, FJ
    CANCER INVESTIGATION, 1999, 17 (02) : 137 - 144
  • [46] Early prostate cancer: is there a need for new treatment options?
    Klimberg, I
    Locke, DR
    Madore, RA
    Smith, WW
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (02) : 105 - 116
  • [47] Pharmacoeconomics of available treatment options for metastatic prostate cancer
    Zeliadt, Steven B.
    Penson, David F.
    PHARMACOECONOMICS, 2007, 25 (04) : 309 - 327
  • [48] Narrowing the options: The process of deciding on prostate cancer treatment
    O'Rourke, ME
    CANCER INVESTIGATION, 1999, 17 (05) : 349 - 359
  • [49] Localized and Locally Advanced Prostate Cancer: Treatment Options
    Achard, Verane
    Panje, Cedric Michael
    Engeler, Daniel
    Zilli, Thomas
    Putora, Paul Martin
    ONCOLOGY, 2021, : 413 - 421
  • [50] A review of the current epidemiology and treatment options for prostate cancer
    Saman, Daniel M.
    Lemieux, Andrine M.
    Lutfiyya, May Nawal
    Lipsky, Martin S.
    DM DISEASE-A-MONTH, 2014, 60 (04): : 150 - 154